Comparative Dosing of Adjunctive Corticosteroids Therapy for Pneumocystis Pneumonia with ARDS in Non-HIV Immunocompromised Patients
Infection and Drug Resistance · 2024-12 · Volume 17 · 5545-5555
DOI: 10.2147/idr.s493298 ↗Kurz gefasst
Fachartikel in der Zeitschrift Infection and Drug Resistance, 2024-12. Verfasst von Xuyan Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical Unive…. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background
Adjuvant corticosteroids are effective in patients with human immunodeficiency virus (HIV)-associated Pneumocystis jirovecii pneumonia (PCP) patients, but the effectiveness of adjuvant corticosteroids in non-HIV PCP remained controversial. This study aimed to evaluate the effectiveness of standard-dose compared with low-dose steroids in non-HIV PCP patients with acute respiratory distress syndrome (ARDS).
Methods
This retrospective observational study included non-HIV PCP patients with ARDS admitted to the respiratory intensive care unit (RICU) of Beijing Chao-Yang Hospital from 2015 to 2022. Demographics, clinical characteristics, and outcomes were compared between patients receiving standard-dose and those receiving low-dose steroids. Survival times were assessed using Kaplan-Meier curves and compared with the Log rank test. Cox proportional hazards regression analysis was conducted to identify independent risk factors for 28-day and 60-day mortality.
Results
A total of 105 non-HIV PCP with ARDS were included, with 48 patients in the standard-dose steroid group (66.7% male, 50.5±12.6 years) and 57 in the low-dose steroid group (61.4% male, 55.5±14.2 years). The 60-day mortality was lower in the standard-dose group than in the low-dose group (63.2% vs 48.3%, p=0.04), while 28-day mortality showed no significant difference (50.8% vs 35.4%, p=0.11). After adjusting for confounders, standard-dose steroids reduced 28-day mortality (aHR: 0.339, 95% CI: 0.147-0.780) and 60-day mortality (aHR: 0.328, 95% CI: 0.152-0.709), particularly in patients aged
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, People's Republic of China.
- Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Beijing, 100029, People's Republic of China.
- National Clinical Research Center for Respiratory Diseases, Beijing, 100029, People's Republic of China.
- Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China.
- Department of Respiratory Medicine, Capital Medical University, Beijing, 100069, People's Republic of China.
Zitieren
APA
Li, X., Guan, L., Wang, D., Tang, X., Wang, R., Li, Y., Tong, Z., Sun, B., & Wang, C. (2024). Comparative Dosing of Adjunctive Corticosteroids Therapy for Pneumocystis Pneumonia with ARDS in Non-HIV Immunocompromised Patients. Infection and Drug Resistance, Volume 17, 5545-5555. https://doi.org/10.2147/idr.s493298
Vancouver
Li X, Guan L, Wang D, Tang X, Wang R, Li Y, et al. Comparative Dosing of Adjunctive Corticosteroids Therapy for Pneumocystis Pneumonia with ARDS in Non-HIV Immunocompromised Patients. Infection and Drug Resistance. 2024;Volume 17:5545-5555. doi:10.2147/idr.s493298
BibTeX
@article{Li2024,
author = {Li, Xuyan and Guan, Lujia and Wang, Dong and Tang, Xiao and Wang, Rui and Li, Ying and Tong, Zhaohui and Sun, Bing and Wang, Chen},
title = {Comparative Dosing of Adjunctive Corticosteroids Therapy for Pneumocystis Pneumonia with ARDS in Non-HIV Immunocompromised Patients},
journal = {Infection and Drug Resistance},
year = {2024},
volume = {Volume 17},
pages = {5545--5555},
doi = {10.2147/idr.s493298}
}
EUVIMED